Jay T. Backstrom - 13 Nov 2025 Form 4 Insider Report for LAVA Therapeutics NV (LVTX)

Role
Director
Signature
/s/ Amy Garabedian, Attorney-in-Fact
Issuer symbol
LVTX
Transactions as of
13 Nov 2025
Transactions value $
$0
Form type
4
Filing time
17 Nov 2025, 16:30:14 UTC
Previous filing
10 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Backstrom Jay T. Director C/O LAVA THERAPEUTICS N.V., YALELAAN 62, UTRECHT, NETHERLANDS /s/ Amy Garabedian, Attorney-in-Fact 17 Nov 2025 0001796398

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LVTX Share Options (Right to Buy) Disposed to Issuer $0 -33.4K -100% $0.00 0 13 Nov 2025 Common Shares 33.4K $0.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jay T. Backstrom is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.